Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435987 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1LMNAMAPTESR2 | |
| SCHEMBL3480240 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1ESR2 | |
| SCHEMBL4423118 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1ESR2 | |
| SCHEMBL3480237 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1ESR2 | |
| SCHEMBL3480330 | 0.84 | PTGS2 (0.40) | PTGS2LMNAMAPTESR2 | |
| SCHEMBL3480327 | 0.84 | PTGS2 (0.40) | PTGS2LMNAMAPTESR2 | |
| SCHEMBL3480407 | 0.79 | PTGS2 (0.36) | PTGS2LMNAMAPTESR2 | |
| SCHEMBL3480411 | 0.79 | PTGS2 (0.36) | PTGS2LMNAMAPTESR2 | |
| SCHEMBL4435494 | 0.79 | PTGS2 (0.48) | PTGS2PTGS1ESR2 | |
| SCHEMBL4435487 | 0.79 | PTGS2 (0.48) | PTGS2PTGS1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495029-B2 | Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke | MERCK & CO., INC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1814838-A2 | PRODRUGS OF (2R)-2-PROPYLOCTANOIC ACID FOR TREATMENT OF STROKE | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006055381-A2 | PRODRUGS OF (2R)-2-PROPYLOCTANOIC ACID FOR TREATMENT OF STROKE | MERCK & CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006044230-A1 | WATER SOLUBLE PRODRUGS OF COX-2 INHIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132488-A1 | Prodrugs of (2R)-2-Propyloctanoic Acid For the Treatment of Stroke | APEH, HCAR2, PTGDR | PTGS2 12/4885PTGS1 43/4885LMNA 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.